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The  advent  of  next-generation  sequencing  technologies  had  a  profound  impact  on  molecular  diagnostics.
PCR  is  a popular  method  for target  enrichment  of disease  gene  panels.  Using  our  proprietary  primer-
design  pipeline,  primerXL,  we have  created  almost  one  million  assays  covering  over  98%  of the  human
exome.  Here  we  describe  the  assay  speciﬁcation  and  both  in  silico  and  wet-lab  validation  of  a  selectedvailable online 9 October 2015
eywords:
CR
ext-generation sequencing
anger sequencing
set  of  2294  assays  using  both  next-generation  sequencing  and  Sanger  sequencing.  Using  a  universal  PCR
protocol  without  optimization,  these  assays  result  in high  coverage  uniformity  and  limited  non-speciﬁc
coverage.  In addition,  data  indicates  a  positive  correlation  between  the  predictive  in  silico  speciﬁcity  score
and the  amount  of assay  non-speciﬁc  coverage.
©  2015  The  Authors.  Published  by  Elsevier  GmbH.  This  is  an  open  access  article  under  the  CC
mpliﬁcation speciﬁcity
. Introduction
The Online Mendelian Inheritance in Man  (OMIM) database cur-
ently contains over 4400 human inherited diseases with a known
enetic cause [1]. Over 300 new disease genes are being identiﬁed
early, with novel mutations accumulating at a rate of 10,000 per
nnum [2]. The establishment of a molecular diagnosis in a family
onﬁrms the clinical diagnosis, enables reproductive options, and,
ore recently, is a prerequisite for gene-speciﬁc therapies. Indeed,
everal ongoing clinical trials for human gene and gene-speciﬁc
herapy emphasize the advent of personalized genomic medicine
3].
Over the past decade, molecular diagnostic testing has faced an
xponential growth due to the replacement of laborious gene-by-
ene Sanger sequencing by parallel resequencing of multiple genes
ith massively parallel or so-called next-generation sequenc-
ng (NGS) technologies. Various target enrichment strategies are
vailable, enabling the customer to resequence any region of inter-
st. Molecular diagnostic laboratories often develop customized
GS platforms, offering a speciﬁc diagnostic portfolio. In addi-
ion to gene centric analyses, both exome and genome sequencing
re appealing NGS approaches because of the greatly decreased
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sequencing cost per base [4]. Thus far, these are not yet routinely
used in diagnostics because of data quality and ethical reasons,
i.e. insufﬁcient coverage for relevant genes and incidental ﬁndings,
respectively. As most genetic centres are accredited, strict regu-
lations are applicable regarding variant reporting [5,6]. Variants
identiﬁed through NGS generally require conﬁrmation using either
NGS or Sanger sequencing. Based on a survey we  did in September
2014, almost 70% of 178 respondents from Europe, USA and Asia
indicated they are currently validating their NGS ﬁndings using
either NGS or Sanger sequencing (Fig. 1A). According to this survey,
PCR ampliﬁcation is the most commonly used target enrichment
method, followed by hybridization (Fig. 1B).
So far, the currently available NGS enrichment methods for
gene panels are hampered by technical limitations. Capture based
enrichment for instance often struggles with GC content or repeat
rich regions. On the other hand, major advantages of PCR-based
enrichment include high ﬂexibility when using singleplex PCR and
cost-effectiveness in case of automation or multiplex PCR [7–9]. Of
note, PCR based enrichment is sensitive to allelic dropout and/or
lower ampliﬁcation efﬁciency caused by single nucleotide poly-
morphisms (SNP) in primer annealing sites and requires more
optimization in case of less efﬁcient PCR assays [10]. We  recently
developed a primer design pipeline for targeted resequencing PCR
assays, called primerXL, tackling these issues [11]. PrimerXL makes
use of the third-party software packages primer3 v3.2.2 (primer
design), UNAFold v3.8 (secondary structures) and Bowtie v0.12.7
(speciﬁcity) and includes optimized settings to maximize target
le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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aig. 1. Distribution of respondents’ (n = 178) answers on two survey questions, (A
creening experiments, if so how do you enrich your targets?
overage while minimizing off-target ampliﬁcation [12–14]. Each
f the assay designs is put through a series of stringent in silico tests
o ﬁlter out primer pairs harbouring secondary structures or SNPs
n their annealing sites, or having non-speciﬁc ampliﬁcation poten-
ial (because of sequence homology to off-target regions). Together,
his results in robust PCR assays ampliﬁable under uniform condi-
ions. Using primerXL, two databases containing almost one million
re-designed sets of assays were developed, each covering ∼98%
f the exonic regions of all human protein coding genes. The main
pplications of these assays are the development of gene panels and
alidation of variants located in exonic regions. A selection of the
ssays has successfully been used in the development of NGS gene
anels for congenital blindness, deafness and cancer [7,15,16]. In
ddition, these assays were used to replace Sanger-based sequenc-
ng with NGS for over 200 genes in an ISO15189-accreditated
etting by our diagnostics department [8]. The goal of this study
as to further determine the applications for these assays and their
verall wet-lab success rate.
. Material and methods
.1. (Quantitative) PCR
Each reaction was performed in a 10 L volume: 5 L Kapa 2G
astermix, 2.5 L primers (forward and reverse oligos mixed at a
 M concentration) and 2.5 L DNA template (20 ng/L). For sam-
le 1, an additional 0.5 L LCGreen Plus (Bioké) was  added since this
ample was assessed using qPCR. All (q)PCR reactions were run on
 Roche LC480 instrument using the following protocol: (1) 180 s
t 95 ◦C, (2) 15 s at 95 ◦C, (3) 10 s at 60 ◦C, (4) 15 s at 72 ◦C, (5) 60 s
t 72 ◦C. Steps 2–4 were repeated 35 times. For sample 1, this was
ollowed by running a melting curve starting at 65 ◦C up to 95 ◦C
ith 0.5 ◦C temperature increments each 5 s.
.2. Library prep and sequencing
Following (q)PCR all reactions were pooled (no normalization
as performed). Concentration measurement was performed with
he Qubit Fluorometer (Life Technologies). A total of 2.5 g of the
ooled PCR product was used as input for the NEBNext DNA Library
rep Master Mix  Set for Illumina (New England BioLabs). During
ach step, 2 L was retained to assess the quality of the prep by
eans of a Bioanalyzer analysis. Both samples were sequenced on
 single Illumina MiSeq run (2 × 150 cycles).ou validate your NGS ﬁndings and if yes, using what method, (B) do you perform
3. Results
3.1. Assay speciﬁcations
Two  assay databases were created with different applications
in mind. The ﬁrst catalogue, with ∼320,000 assays having ampli-
con lengths between 350–750 bp (with 65.2% between 350–450),
is optimized for high-quality DNA samples. The second catalogue,
suited for fragmented DNA (e.g. derived from FFPE samples), con-
tains almost 550,000 short assays (amplicon lengths: 125–275 bp).
The latter assays are also ideal candidates for multiplex PCR because
of their uniform amplicon lengths. Both databases have been gener-
ated to cover all exons of all Ensembl canonical transcripts (Ensembl
build 63). The exome coverage for the long and short dataset is
97.99% and 98.71%, respectively. Since then, the in silico SNP and
speciﬁcity analysis was reassessed for the longest amplicons using
a more recent genome build (Ensembl build 78). In 94.01% of these
assays, no SNPs are present in the primer annealing sites. For the
remaining assays, 85.74% contain SNP(s) outside the critical 5 bp
3′ region, whereas 92.47% contain only a single SNP. The in sil-
ico speciﬁcity analysis determined the likelihood of non-speciﬁc
product generation for each assay. This was done by Bowtie-based
alignment of an assay to the human genome (hg38), allowing up
to 3 mismatches per primer (3 or more mismatches signiﬁcantly
impede the ampliﬁcation process), and assigning each assay an in
silico speciﬁcity score equal to the minimal number of mismatches
across all predicted off-target hits [10,12]. The higher the resulting
speciﬁcity level, the more speciﬁc the assays are predicted to be.
A speciﬁcity level of 7 means that there are no non-speciﬁc hits,
whereas a speciﬁcity level of 5 for e.g.  refers to predicted off-target
hits with three mismatches in one primer and two mismatches in
the other primer. This analysis revealed that the majority (73.1%) of
assays attain the most stringent speciﬁcity level (i.e.  level 7) (Fig. 2).
All assays are linked to their speciﬁcity level and SNP information,
which is displayed to the user upon querying the database.
3.2. Wet-lab assay validation
From the 350–750 bp dataset, 2294 assays covering 169 diag-
nostically relevant diseases were randomly selected. Using these
assays, singleplex ampliﬁcation was performed on two pooled sam-
ples containing male and female DNA.To assess assay performance and end-point equimolarity, quan-
titative PCR was used for sample 1, while classical PCR was
performed for sample 2. Following ampliﬁcation using a universal
protocol (KAPA 2G Robust–spiked with LCGreen Plus for sample
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qPCR ok, no on-target coverageig. 2. Distribution of the number of assays in the 350–750 bp assay set in function
f  the in silico speciﬁcity score.
), products were pooled per sample and prepped for sequencing
sing the NEBNext DNA Library Prep Master Mix Set for Illumina
New England BioLabs). Both samples were sequenced on a sin-
le Illumina MiSeq run (2 × 150 cycles) generating 3,819,421 and
,747,843 reads, respectively. A custom mapping strategy was
pplied to determine the speciﬁcity level of each assay. To assign
eads to their corresponding assay, the ﬁrst 50 nucleotides of the
rst read-pair were concatenated with the reverse complement of
he ﬁrst 50 nucleotides of the second read-pair, thus generating a
asta ﬁle. This ﬁle was used as a reference sequence against which
ach assay was mapped in paired-mode using Bowtie allowing up
o three mismatches and a 100 bp maximum product size. For each
equencing read, the read/assay combination having the least num-
er of mapping mismatches was then considered the correct one.
n this way, a total of 3,457,533 (sample A, 90.5%) and 3,319,688
sample B, 88.6%) reads could be assigned to the various assays. A
ummary of (q)PCR and sequencing results for both samples can be
een in Fig. 3.
Overall, coverage uniformity per assay was high, with 60% and
8.8% of the assay having a coverage within 2-fold of the mean for
ample A (mean = 1551) and B (mean = 1487) respectively (83.3%
nd 82.6% within 5-fold of the mean) (Fig. 4). No correlation
etween read-depth and qPCR end-point ﬂuorescence values for
ample 1 was observed (data not shown). Of note, the end-point
uorescence values showed highly uniform product equimolarity
95.95% of the assays have an end-point ﬂuorescence value within
-fold of the mean), obviating the need for time-consuming product
ormalization prior to sequencing. Coverage speciﬁcity per assay
as determined by calculating the ratio between the number of
ssociated (on-target) reads overlapping the genomic coordinates
f the assay and all reads (both on- and off-target) linked to that
ssay. Results indicated that less than 12.0% and 12.8% of the assays,
or sample A and B respectively, had more than 2% of its associatedqPCR ok, on-target coverage
Fig. 3. Overview of the coverage results for the 2294 assays in both samples.
reads mapping to off-target regions (Fig. 5). As mentioned earlier,
each assay is assigned an in silico speciﬁcity score. For this experi-
ment, the in silico assay speciﬁcity score was determined by means
of a Bowtie alignment with a maximum hit size of 1500 bp. For each
score, the percentage of assays with more than 2% off-target was
calculated. Fig. 6 shows there is a correlation between the percent-
age of assays having a higher degree of non-speciﬁcity and the in
silico speciﬁcity score, conﬁrming the predictive value of the latter
with respect to off-target sequencing coverage.
In addition to NGS, 1900 out of 2294 pxlence assays were also
subjected to Sanger sequencing using a universal ampliﬁcation and
sequencing protocol. This was  performed in a ISO15189 accredited
lab in the context of comparing and replacing Sanger-based diag-
nostic tests with NGS [8]. In practice, Sanger sequencing was only
performed for assays passing LabChip GX (PerkinElmer) assess-
ment. The overall success rate of the pxlence assays on LabChip
GX was  95.77%. Subsequent Sanger sequencing of 1900 pxlence
assays revealed a Sanger success rate of 88.63%. The most common
observations in case of failed Sanger sequencing where (1) com-
pletely failed Sanger traces possibly due to the amplicon sequence
contents, (2) the presence of pseudogenes and (3) the presence of
homopolymeric regions close (downstream) to the primers, caus-
ing uninterpretable traces early in the sequence.
4. Discussion
We  have generated pre-designed assays covering over 98% of the
human exome using an in-house developed primer-design pipeline
called primerXL. All assays have thoroughly been tested in silico
resulting in robust assay performance while minimizing poten-
tial aspeciﬁc ampliﬁcation. An extensive singleplex wet-lab qPCR
ampliﬁcation experiment showed that the majority (94.73% have
more than 20× on-target coverage) of these off-the-shelf assays
work well without any need for optimization, reducing the time
required to enrich targets. Although not tested in this study, we
anticipate that the short assays could be good candidates for mul-
tiplex PCR because of their uniform amplicon lengths and primer
properties. Sequencing coverage uniformity is high, with limited
sequencing drop-out (3.71% have less than 20× total coverage)
while non-speciﬁc coverage is kept to a minimum. This, together
with the results of our small-scale market study, indicate that these
assays, available for both normal quality as well as fragmented
F. Coppieters et al. / Biomolecular Detection and Quantiﬁcation 6 (2016) 22–26 25
Fig. 4. Cummulative distribution of the coverage per amplicon, both total coverage and on-target coverage. Areas show the 2-fold region around the mean for each sample.
sample B (n=2233)
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Fig. 5. Percentage of assays with more than 98% of the reads mapping to on-target regions.
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